World Journal of Urology

, Volume 32, Issue 1, pp 9–18

The ineligible patient: how to treat patients not included in clinical studies

Topic Paper

Abstract

Purpose

Targeted therapies are currently the standard of care for metastatic renal cell carcinoma (mRCC). Five VEGF pathway inhibitors (sorafenib, sunitinib, bevacizumab in combination with interferon-alpha, pazopanib, and axitinib) and two mTOR inhibitors (everolimus and temsirolimus) are now FDA approved for mRCC based on results from phase III randomized clinical trials (RCTs). However, several subgroups of patients are excluded from enrollment due to strict eligibility criteria. The toxicity and efficacy of targeted therapies in these populations are unknown.

Methods

PubMed was searched for citations of the pivotal phase III RCTs leading to FDA approval. These publications were cross-referenced with their associated entries on www.ClinicalTrials.gov, and both were abstracted for eligibility criteria for patient enrollment. Based on this data, PubMed was searched for both prospective and retrospective studies evaluating toxicity and efficacy of targeted therapies for mRCC in these ineligible patient subgroups.

Results

We reviewed published toxicity and efficacy data in several ineligible patient subgroups, including patients with non-clear cell renal cell carcinoma, poor performance status, poor renal function, CNS metastases, significant cardiac comorbidities, and prior systemic therapy.

Conclusions

Targeted therapies appear to be safe in most ineligible patient populations, including patients with poor renal function. However, patients with preexisting cardiac comorbidities are at greater risk of developing cardiac toxicity on sunitinib. Targeted therapies appear to have some efficacy in maintaining stable disease in these subgroups, but are limited to rare partial responses. Prospective cohort studies are needed to accurately assess the safety and efficacy of targeted therapies in ineligible patient subgroups.

Keywords

Metastatic renal cell carcinoma Ineligible patients Targeted therapy Sunitinib Axitinib Pazopanib Sorafenib Everolimus Temsirolimus Bevacizumab 

References

  1. 1.
    Schlesinger-Raab A, Treiber U, Zaak D, Hölzel D, Engel J (2008) Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up. Eur J Cancer 44(16):2485–2495PubMedCrossRefGoogle Scholar
  2. 2.
    Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340:c869PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Schulz K, Grimes D (2002) Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 359:781–785PubMedCrossRefGoogle Scholar
  4. 4.
    Braunholtz DA, Edwards SJ, Lilford RJ (2001) Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”. J Clin Epidemiol 54(3):217–224PubMedCrossRefGoogle Scholar
  5. 5.
    Peppercorn JM, Weeks JC, Cook EF, Joffe S (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363(9405):263–270PubMedCrossRefGoogle Scholar
  6. 6.
    Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD (2008) Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev (3):MR000009. doi:10.1002/14651858.MR000009.pub4
  7. 7.
    Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281PubMedCrossRefGoogle Scholar
  8. 8.
    Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216PubMedCrossRefGoogle Scholar
  9. 9.
    Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150PubMedCrossRefGoogle Scholar
  10. 10.
    Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33):5422–5428PubMedCrossRefGoogle Scholar
  11. 11.
    Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134PubMedCrossRefGoogle Scholar
  12. 12.
    Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939PubMedCrossRefGoogle Scholar
  13. 13.
    Motzer R, Bander N, Nanus D (1996) Renal-cell carcinoma. N Engl J Med 335(12):865–875PubMedCrossRefGoogle Scholar
  14. 14.
    Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z (2006) 2004 WHO classification of the renal tumors of the adults. Eur Urol 49(5):798–805PubMedCrossRefGoogle Scholar
  15. 15.
    Deng F-M, Melamed J (2012) Histologic variants of renal cell carcinoma: does tumor type influence outcome? Urol Clin N Am 39(2):119–132CrossRefGoogle Scholar
  16. 16.
    Dutcher JP, De Souza P, McDermott D, Figlin Ra, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G (2009) Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26(2):202–209PubMedCrossRefGoogle Scholar
  17. 17.
    Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757–763PubMedCrossRefGoogle Scholar
  18. 18.
    Stadler WM, Figlin RA, McDermott DF et al (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116(5):1272–1280PubMedCrossRefGoogle Scholar
  19. 19.
    Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26(1):127–131PubMedCrossRefGoogle Scholar
  20. 20.
    Tannir NM, Plimack E, Ng C, et al (2012) A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. doi: 10.1016/j.eururo.2012.06.043
  21. 21.
    Motzer R, Mazumdar M (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540PubMedGoogle Scholar
  22. 22.
    Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22(3):454–463PubMedCrossRefGoogle Scholar
  23. 23.
    Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110(3):543–550PubMedCrossRefGoogle Scholar
  24. 24.
    Beck J, Procopio G, Bajetta E et al (2011) Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 22(8):1812–1823PubMedCrossRefGoogle Scholar
  25. 25.
    Gupta S, Parsa V, Heilbrun L, Smith D, Dickow B, Heath E, Vaishampayan U (2009) Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients with renal insufficiency (RI). J Clin Oncol 27(15 s):suppl; abstr 5108Google Scholar
  26. 26.
    Josephs D, Hutson T (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 108(8):1279–1283PubMedCrossRefGoogle Scholar
  27. 27.
    Khosravan R, Toh M, Garrett M, La Fargue J, Ni G, Marbury TC, Swan SK, Lunde NM, Bello CL (2010) Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 50(4):472–481PubMedCrossRefGoogle Scholar
  28. 28.
    Pfizer (2011) Sutent: highlights of prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id=607. Accessed 11 Sep 2012
  29. 29.
    Macfarlane R, Heng DYC, Xie W, Knox JJ, McDermott DF, Rini BI, Kollmannsberger C, Choueiri TK (2012) The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. Cancer 118(2):365–370PubMedCrossRefGoogle Scholar
  30. 30.
    Saitoh H (1981) Distant metastasis of renal adenocarcinoma. Cancer 48(6):1487–1491PubMedCrossRefGoogle Scholar
  31. 31.
    Wronski M, Maor MH, Davis BJ, Sawaya R, Levin VA (1997) External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37(4):753–759Google Scholar
  32. 32.
    Nieder C (1999) Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 85(1):251–253PubMedCrossRefGoogle Scholar
  33. 33.
    Culine S, Bekradda M, Kramar A, Rey A, Escudier B, Droz JP (1998) Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 83(12):2548–2553PubMedCrossRefGoogle Scholar
  34. 34.
    Verma J, Jonasch E, Allen P, Tannir N, Mahajan A (2011) Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117(21):4958–4965PubMedCrossRefGoogle Scholar
  35. 35.
    Gore ME, Hariharan S, Porta C et al (2011) Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117(3):501–509PubMedCrossRefGoogle Scholar
  36. 36.
    Telli ML, Witteles RM, Fisher GA, Srinivas S (2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19(9):1613–1618PubMedCrossRefGoogle Scholar
  37. 37.
    Di Lorenzo G, Autorino R, Bruni G et al (2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20(9):1535–1542PubMedCrossRefGoogle Scholar
  38. 38.
    Richards CJ, Je Y, Schutz FAB, Heng DYC, Dallabrida SM, Moslehi JJ, Choueiri TK (2011) Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 29(25):3450–3456PubMedCrossRefGoogle Scholar
  39. 39.
    Greineder CF, Kohnstamm S, Ky B (2011) Heart failure associated with sunitinib: lessons learned from animal models. Curr Hypertens Rep 13(6):436–441PubMedCrossRefGoogle Scholar
  40. 40.
    Gupta R, Maitland ML (2011) Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity. Curr Hypertens Rep 13(6):430–435PubMedCrossRefGoogle Scholar
  41. 41.
    Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124PubMedCrossRefGoogle Scholar
  42. 42.
    Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111PubMedCrossRefGoogle Scholar
  43. 43.
    Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456PubMedCrossRefGoogle Scholar
  44. 44.
    Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256–4265PubMedCrossRefGoogle Scholar
  45. 45.
    (2012) National comprehensive cancer network guidelines for kidney cancer. http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed 19 Sep 2012
  46. 46.
    Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48(3):333–339PubMedCrossRefGoogle Scholar
  47. 47.
    Calvo E, Ravaud A, Bellmunt J (2012) What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat Rev. doi: 10.1016/j.ctrv.2012.06.010
  48. 48.
    Heng DY, Choueiri TK, Lee J-L et al (2012) A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials. J Clin Oncol 30(Suppl 5):abstr 353Google Scholar
  49. 49.
    Rini BI, Halabi S, Rosenberg JE et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137–2143Google Scholar
  50. 50.
    Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068Google Scholar
  51. 51.
    Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20):3312–3318Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of MedicineCleveland Clinic Lerner College of MedicineClevelandUSA
  2. 2.Department of Solid Tumor Oncology, Glickman Urological InstituteCleveland Clinic Taussig Cancer InstituteClevelandUSA

Personalised recommendations